Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models
Authors:
- 1 July 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 61, 20-28
Abstract
No abstract availableKeywords
Funding Information
- Ruspharmtech LLC
- Skolkovo
This publication has 30 references indexed in Scilit:
- Functional Analysis of a Breast Cancer-Associated FGFR2 Single Nucleotide Polymorphism Using Zinc Finger Mediated Genome EditingPLOS ONE, 2013
- A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma XenograftsMolecular Cancer Therapeutics, 2012
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer ModelsMolecular Cancer Therapeutics, 2012
- Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinomaJournal of Clinical Investigation, 2011
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor XenograftsClinical Cancer Research, 2010
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 ExpressionPLOS ONE, 2010
- Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 IsoformJournal of Biological Chemistry, 2009
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Involvement of Fibroblast Growth Factor Receptor 2 Isoform Switching in Mammary OncogenesisMolecular Cancer Research, 2008
- The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer developmentThe EMBO Journal, 2007